Showing items 1 - 20 of 70

Your selections:

Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?

When to choose radiotherapy for prostate cancer, and what technique?

Urinary symptoms following external beam radiotherapy of the prostate: Dose-symptom correlates with multiple-event and event-count models

Tumor innervation and clinical outcome in pancreatic cancer

Treatment-related morbidity in prostate cancer: a comparison of 3-dimensional conformal radiation therapy with and without image guidance using implanted fiducial markers

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial

Thrombin generation as a predictor of radiotherapy induced skin erythema

The radiotherapeutic injury: a complex 'wound'

The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancer

Technical quality assurance during the TROG 03.04 RADAR prostate radiotherapy trial: are the results reflected in observed toxicity rates?

Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials

Statistical-learning strategies generate only modestly performing predictive models for urinary symptoms following external beam radiotherapy of the prostate: a comparison of conventional and machine-learning methods

Spatial features of dose-surface maps from deformably-registered plans correlate with late gastrointestinal complications

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial

Serum procollagen 1 amino-terminal propeptide (P1NP) in prostate cancer: pitfalls of its use as an early surrogate marker for bone metastasis

Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis

Risk stratification after biochemical failure following curative treatment of locally advanced prostate cancer: data from the TROG 96.01 trial

Researching depression in prostate cancer patients: factors, timing, and measures

Relationships between rectal and perirectal doses and rectal bleeding or tenesmus in pooled voxel-based analysis of 3 randomised phase III trials

  • Disclaimer
  • Privacy
  • Copyright
  • Contact
  • Deposit